BillionToOne reported earnings of $0.15 per diluted share for Q2, missing the $0.19 consensus, while revenue jumped 64% to $109.4 million. The miss underscores pricing pressure, yet the revenue surge and 70% gross margin suggest strong demand for its prenatal and oncology tests, keeping the stock attractive to growth investors.
Key Highlights
- Q2 revenue $109.4 million, up 64% YoY, driven by 55% rise in prenatal testing and 176% jump in oncology testing
- Gross profit margin improved to 70% from 65% a year earlier, reflecting a higher overall ASP of $551
- Operating income turned positive to $5.5 million, while free cash flow reached $5.1 million
BillionToOne (NASDAQ: BLLN) posted second‑quarter revenue of $109.4 million, a 64% year‑over‑year increase, while earnings per share slipped to $0.15 against a $0.19 consensus estimate. The surge was powered by a $94.2 million boost in prenatal testing and a $13.7 million surge in oncology testing, delivering a 70% gross profit margin.
Q2 Revenue Surge
Revenue climbed from $66.6 million a year earlier to $109.4 million, propelled by 55% growth in prenatal clinical testing and a 176% jump in oncology testing. Test deliveries rose 35% to 196,000, while the overall average selling price increased 21% to $551, lifting gross margin to 70% from 65% in the prior year. The operating loss turned to a $5.5 million profit, highlighting disciplined cost control.
This mix of volume expansion and price power demonstrates the scalability of the company’s smNGS platform, suggesting that future product rollouts could further amplify top‑line momentum.
Operational Metrics Deep Dive
Gross profit of $77.1 million translated into a 70% margin, driven by higher ASP and efficient cost per test despite an uptick in oncology test share, which carries higher costs. Operating expenses rose 59% to $71.6 million, reflecting continued investment in R&D and commercial expansion. Free cash flow of $5.1 million underscores the firm’s ability to fund growth without external financing.
The shift from a $1.6 million operating loss to a $5.5 million operating profit signals a turning point in profitability, reinforcing confidence that the business can sustain margins while scaling its test portfolio.
Market Context and Investor Sentiment
Sector peers LH rose 0.3%, BTSG held steady, and DVA edged up 0.2%, showing relative strength for BillionToOne. The earnings miss is tempered by the strong revenue growth and expanding gross margin, which align with investor appetite for high‑growth molecular diagnostics firms. This performance suggests that the market may re‑price the stock as new product launches materialize, rewarding sustained demand for advanced prenatal and oncology assays.
Forward Catalyst
The company will debut an expanded Unity Fetal Risk Screen with a 130‑gene panel on August 17, 2026, and launch the Northstar Origin tissue‑of‑origin add‑on on September 1, 2026. Management will discuss the quarter’s results and growth strategy during a conference call on August 5, 2026. These events provide investors with concrete milestones to gauge execution of the product roadmap, and the outcomes could drive the next wave of revenue acceleration.
Peers Moving on This News
- Labcorp Holdings Inc (LH) up 0.3%
- Brightspring Health Services Inc (BTSG) little changed
- DaVita Inc (DVA) up 0.2%
Analysis based on the Form 8-K filed 5 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...